Catalyst Pharmaceuticals, Inc. (CPRX)
Jul 15, 2026 - CPRX was delisted (reason: acquired by Angelini Pharma)
31.49
0.00 (0.00%)
Inactive · Last trade price on Jul 15, 2026
Catalyst Pharmaceuticals Stock Forecast
Stock Price Forecast
According to 4 analysts polled by S&P Global, Catalyst Pharmaceuticals stock has a consensus rating of "Hold" and an average price target of $31.67. The average 1-year stock price forecast is 0.57% higher than the current stock price, while the lowest is $31.5 (+0.03%) and the highest is $32 (+1.62%).
Price Target: $31.67 (+0.57%)
Analyst Consensus: Hold
Price Target
ChartAnalyst Ratings
The average analyst rating for Catalyst Pharmaceuticals stock from 4 stock analysts was "Hold". This means that analysts believed this stock was likely to perform similarly to the overall market.
Recommendation Trends
| Rating | Jan '26 | Feb '26 | Mar '26 | Apr '26 | May '26 | Jun '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 7 | 7 | 7 | 7 | 1 | 0 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 5 | 4 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 7 | 7 | 7 | 7 | 6 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| H.C. Wainwright | H.C. Wainwright | Buy Reiterates $26 → $30 | Buy | Reiterates | $26 → $30 | -4.73% | Jul 9, 2026 |
| Citi | Citi | Hold Downgrades $35 → $32 | Hold | Downgrades | $35 → $32 | +0.03% | May 8, 2026 |
Unknown Analyst Robert W. Baird No rating | Robert W. Baird | Hold Downgrades $32 | Hold | Downgrades | $32 | +1.62% | May 7, 2026 |
| Oppenheimer | Oppenheimer | Hold Downgrades n/a | Hold | Downgrades | n/a | n/a | May 7, 2026 |
| Stephens | Stephens | Hold Downgrades $32 | Hold | Downgrades | $32 | +1.62% | May 7, 2026 |
Financial Forecast
Revenue This Year
636.20M
from 588.99M
Increased by 8.02%
Revenue Next Year
717.90M
from 636.20M
Increased by 12.84%
EPS This Year
3.17
from 2.72
Increased by 16.69%
EPS Next Year
3.18
from 3.17
Increased by 0.22%
EPS and Forward PE are based on non-GAAP adjusted numbers.